Bringing the fundamentals into focus…
Back to Spyre Therapeutics, Inc.
How Spyre Therapeutics, Inc. stacks up
SYRE · against 1,336 other Healthcare companies
Valuation
33/ 100
Below the middle of the pack.
Ranked #857 of 1,337 · scores higher than 33% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 30–39, including SYRE · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.9% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -2.4% vs peer median 0.0%
- EBITDA yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = SYRE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SYRE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -1.9% | 1.5% | 34% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | Not reported | 4.2% | — | — | 50% |
| Free cash flow yieldHigher is better · 711 reported | -2.4% | -1.0% | 45% | 20% | |
| Book yieldHigher is better · 1,306 reported | 10.9% | 37.9% | 16% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around SYRE| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 857 | 191M USD | 33 | 38 | |
| 857 | 165M USD | 33 | 50 | |
| 857 | 1.8B USD | 33 | ||
| 857 | 158M USD | 33 | 14 | |
| 857 | 8.8B USD | 33 | 50 | |
| 857 | 142M USD | 33 | 45 | |
| 857 | 89M USD | 33 | 31 | |
| 857 | 184M USD | 33 | 33 | |
| 857 | 186M USD | 33 | 52 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score